Everolimus (Afinitor®)

DRUG5 trials

Sponsors

Hopital Foch, AIO-Studien-gGmbH, Jiangsu Simcere Pharmaceutical Co., Ltd., Odense University Hospital, The First Affiliated Hospital with Nanjing Medical University

Conditions

Breast CancerLocally Advanced or Metastatic Breast CancerNeuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3Neuroendocrine Carcinoma, Grade 3Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)Poorly Differentiated Malignant Neuroendocrine CarcinomaPostmenopausal Women

Phase 2

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium

CompletedNCT01801137

Hopital FochUrothelial Cancer

Start: 2011-06-30End: 2014-10-31Updated: 2016-06-21

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

CompletedNCT02113800

AIO-Studien-gGmbHNeuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3, Neuroendocrine Carcinoma, Grade 3 +2

Start: 2015-08-31End: 2020-04-30Updated: 2020-10-28

Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women

Active, not recruitingNCT06789900

Odense University HospitalPostmenopausal Women

Start: 2024-10-14End: 2026-10-01Updated: 2026-04-07

A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

RecruitingNCT07900516

The First Affiliated Hospital with Nanjing Medical UniversityBreast Cancer

Start: 2026-08-01End: 2028-08-01Target: 48Updated: 2026-10-28

Phase 3

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Active, not recruitingNCT06680921

Jiangsu Simcere Pharmaceutical Co., Ltd.Locally Advanced or Metastatic Breast Cancer

Start: 2024-11-14End: 2028-08-31Updated: 2026-08-11

Related Papers

SIMRISE: A randomized phase III trial evaluating SIM0270 in combination with everolimus versus treatment of physician’s choice in patients with ER+/HER2- advanced breast cancer, previously treated with CDK4/6 inhibitors.

Journal of Clinical Oncology2025-05-28

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol

BMJ Open2020-07-0120 citations

Feasibility and activity of everolimus in patients (pts) with advanced urothelial carcinoma (UC) pretreated with 2 lines of chemotherapy (CT) including a platinum containing regimen (PCR): The French AFINIVEST study.

Journal of Clinical Oncology2015-05-20